Apolipoprotein e promoter polymorphisms and risk of Alzheimer's disease: Evidence from meta-analysis

Journal of Alzheimer's Disease

Volumn 19, Issue 4, 2010, Pages 1283-1294

  Xin, Xiao Yu ^a   Ding, Jian Qing ^a   Chen, Sheng Di ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

219T G; 427T C; 491A T; Alzheimer's disease; APOE promoter; Meta analysis

Indexed keywords

APOLIPOPROTEIN E;

ALZHEIMER DISEASE; ARTICLE; DNA POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; PRIORITY JOURNAL; PROMOTER REGION;

EID: 77950364668     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1329     Document Type: Article

References (68)

1. Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, Lobo A, Martinez-Lage J, Soininen H, Hofman A (2000) Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54, S10-15.
2. Drzezga A, Grimmer T, Henriksen G, Mühlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschläger A, Riemenschneider M, Wester HJ, Foerstl H, Schwaiger M, Kurz A (2009) Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72, 1487-1494.
3. Maysinger D, Holmes M, Han X, Epand RM, Pertens E, Foerster A, Barlas C, Holtzman DM, Diamond J (2008) Ceramide is responsible for the failure of compensatory nerve sprouting in apolipoprotein E knock-out mice. J Neurosci 28, 7891-7899.
4. Cedazo-Mínguez A (2007) Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med 11, 1227-1238.
5. Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, Goldfarb L, Goldgaber D, Manwaring MG, Szymanski MH, McCown N (1993) Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 342, 710-711.
6. Chartier-Harlin MC, Parfitt M, Legrain S, Ṕerez-Tur J, Brousseau T, Evans A, Berr C, Vidal O, Roques P, Gourlet V, Fruchart JC, Delacourte A, Rossor M, Amouye P (1994) Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet 3, 569-574.
7. Lambert JC, Ṕerez-Tur J, Dupire MJ, Galasko D, Mann D, Amouyel P, Hardy J, Delacourte A, Chartier-Harlin MC (1997) Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. Hum Mol Genet 6, 2151-2154.
8. Artiga MJ, Bullido MJ, Sastre I, Recuero M, García MA, Aldudo J, V́azquez J, Valdivieso F (1998). Allelic polymorphism in the trascriptional region of apolipoprotein E gene. FEBS Lett 421, 105-108.
9. Casas JP, Hingorani AD, Bautista LE, Sharma P (2004) Metaanalysis of genetic studies in ischemic stroke. Thirty-two genes involving approximately 18000 cases and 58000 controls. Arch Neurol 61, 1652-1662.
10. Ntais C, Polycarpou A, Ioannidis JP (2004) Meta-analysis of the association of cathepsin D Ala224Val gene polymorphism with the risk of Alzheimer's disease: a HuGE gene-disease association review. Am J Epidemiol 159, 527-536.
11. Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Sleegers K, Prince JA, van Duijn CM, Kehoe PG (2005) Large meta-analysis establishes theACEinsertion-deletion polymorphism as a marker of Alzheimer's disease. Am J Epidemiol 162, 305-317.
12. Staton JM, Sayer MS, Hankey GJ, Attia J, Thakkinstian A, Yi Q, Cole VJ, Baker R, Eikelboom JW (2006) Association between phosphodiesterase 4D gene and ischaemic stroke. J Neurol Neurosurg Psychiatry 77, 1067-1069.
13. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7, 177-188.
14. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos- IoannidisDG(2003) Genetic associations in large versus small studies: an empirical assessment. Lancet 361, 567-571.
15. Zintzaras E, Rodopoulou P, Sakellaridis N (2009) Variants of the arachidonate 5-lipoxygense- activating protein (ALOX5AP) gene and risk of stroke: a HuGE gene-disease association review and meta-analysis. Am J Epidemiol 169, 523-532.
16. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57, 289-300.
17. Holm S (1979) A Simple Sequentially Rejective Bonferroni Test Procedure. Scand J Stat 6, 65-70.
18. Hedges LV, Pigott TD (2001) The power of statistical tests in meta-analysis. Psychol Methods 6, 203-217.
19. Bullido MJ, Valdivieso F (2000) Apolipoprotein E gene promoter polymorphisms in Alzheimer's disease. Microsc Res Tech 50, 261-267.
20. Laws SM, Hone E, Gandy S, Martins RN (2003) Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE trascription. J Neurochem 84, 1215-1236.
21. Lambert JC, Pasquier F, Cottel D, Frigard B, Amouyel P, Chartier-Harlin MC(1998) Anew polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Hum Mol Genet 7, 533-540.
22. Lambert JC, Araria-Goumidi L, Myllykangas L, Ellis C,Wang JC, Bullido MJ, Harris JM, Artiga MJ, Hernandez D, Kwon JM, Frigard B, Petersen RC, Cumming AM, Pasquier F, Sastre I, Tienari PJ, Frank A, Sulkava R, Morris JC, St Clair D, Mann DM, Wavrant-DeVrìeze F, Ezquerra-Trabalon M, Amouyel P, Hardy J, Haltia M, Valdivieso F, Goate AM, Ṕerez-Tur J, Lendon CL, Chartier-Harlin MC (2002) Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. Neurology 59, 59-66.
23. Beyer K, Lao JI, Ǵomez M, Riutort N, Latorre P, Mate JL, Ariza A (2002) Identification of a protective allele against Alzheimer disease in the APOE gene promoter. Neuroreport 13, 1403-1405.
24. Lambert JC, Berr C, Cottel D, Amouyel P, Helbecque N(2004) APOE promoter polymorphisms and dementia in the elderly. Neurosci Lett 365, 116-119.
25. Bullido MJ, Artiga MJ, Recuero M, Sastre I, García MA, Aldudo J, Lendon C, Han SW, Morris JC, Frank A, V́azquez J, Goate A, Valdivieso F (1998) A polymorphism in the regulatory region of APOE associated with risk of Alzheimer's dementia. Nat Genet 18, 69-71.
26. Song YQ, Rogaeva E, Premkumar S, Brindle N, Kawarai T, Orlacchio A, Yu G, Levesque G, Nishimura M, Ikeda M, Pei Y, O'Toole C, Duara R, Barker W, Sorbi S, Freedman M, Farrer L, St George-Hyslop P (1998) Absence of association between Alzheimer disease and the -491 regulatory region polymorphism of APOE. Neurosci Lett 250, 189-192.
27. Rebeck GW, Cheung BS, Growdon WB, Deng A, Akuthota P, Locascio J, Greenberg SM, Hyman BT (1999) Lack of independent associations of apolipoprotein E promoter and intron 1 polymorphisms with Alzheimer's disease. Neurosci Lett 272, 155-158.
28. Roks G, Cruts M, Bullido MJ, Backhovens H, Artiga MJ, Hofman A, Valdivieso F, Van Broeckhoven C, Van Duijn CM (1998) The -491A/T polymorphism in the regulatory region of the apolipoproteinEgene and early-onsetAlzheimer's disease. Neurosci Lett 258, 65-68.
29. Tycko B, Lee JH, Ciappa A, Saxena A, Li CM, Feng L, Arriaga A, Stern Y, Lantigua R, Shachter N, Mayeux R (2004) APOE and APOC1 promoter polymorphisms and the risk of Alzheimer disease in African and Caribbean Hispanic individuals. Arch Neurol 61, 1434-1439.
30. Artiga MJ, Bullido MJ, Frank A, Sastre I, Recuero M, García MA, Lendon CL, Han SW, Morris JC, V́azquez J, Goate A, Valdivieso F (1998) Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene. Hum Mol Genet 7, 1887-1892.
31. Town T, Paris D, Fallin D, Duara R, Barker W, Gold M, Crawford F, Mullan M (1998) The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism. Neurosci Lett 252, 95-98.
32. Lambert JC, Berr C, Pasquier F, Delacourte A, Frigard B, Cottel D, Ṕerez-Tur J, Mouroux V, Mohr M, Ćecyre D, Galasko D, Lendon C, Poirier J, Hardy J, Mann D, Amouyel P, Chartier-Harlin MC (1998) Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Hum Mol Genet 7, 1511-1516.
33. Ahmed AR, MacGowan SH, Culpan D, Jones RW, Wilcock GK (1999) The -491A/T polymorphism of the Apolipoprotein E gene is associated with the ApoEepsilon4 allele and Alzheimer's disease. Neurosci Lett 263, 217-219.
34. Toji H, Maruyama H, Sasaki K, Nakamura S, Kawakami H (1999) Apolipoprotein E promoter polymorphism and sporadic Alzheimer's disease in a Japanese population. Neurosci Lett 259, 56-58.
35. Helisalmi S, Hiltunen M, Valonen P, Mannermaa A, Koivisto AM, Lehtovirta M, Ryynänen M, Soininen H (1999) Promoter polymorphism (-491A/T) in the APOE gene of Finnish Alzheimer's disease patients and control individuals. J Neurol 246, 821-824.
36. Casadei VM, Ferri C, Veglia F, Gavazzi A, Salani G, Cattaneo M, Sorbi S, Annoni G, Licastro F, Mariani C, Franceschi M, Grimaldi LM (1999) APOE-491 promoter polymorphism is a risk factor for late-onset Alzheimer's disease. Neurology 53, 1888-1889.
37. Thome J, Gewirtz JC, Sakai N, Zachariou V, Retz-Junginger P, RetzW, Duman RS, RöslerM(1999) Polymorphisms of the human apolipoprotein E promoter and bleomycin hydrolase gene: risk factors for Alzheimer's dementia? Neurosci Lett 274, 37-40.
38. Chen L, Baum L, Ng HK, Chan LY, Sastre I, Artíga MJ, Valdivieso F, Bullido MJ, Chiu HF, Pang CP (1999) Apolipoprotein E promoter and alpha2-macroglobulin polymorphisms are not genetically associated with Chinese late onset Alzheimer's disease. Neurosci Lett 269, 173-177.
39. Laws SM, Taddei K, Martins G, Paton A, Fisher C, Clarnette R, Hallmayer J, Brooks WS, Gandy SE, Martins RN (1999) The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease. Neuroreport 10, 879-882.
40. Hu CJ, Sung SM, Liu HC, Hsu WC, Lee LS, Lee CC, Tsai CH, Chang JG (2000) Genetic risk factors of sporadic Alzheimer's disease among Chinese in Taiwan. J Neurol Sci 181, 127-131.
41. Wang JC, Kwon JM, Shah P, Morris JC, Goate A (2000) Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease. Neurology 55, 1644-1649.
42. Halimi G, Duplan L, Bideau C, Iniesta D, Berth́ez̀ene P, Oddoze C, Verdier JM, Michel B, Berǵe-Lefranc JL (2000) Association of APOE promoter but not A2M polymorphisms with risk of developing Alzheimer's disease. Neuroreport 11, 3599-3601.
43. Zurutuza L, Verpillat P, Raux G, Hannequin D, Puel M, Belliard S, Michon A, Pothin Y, Camuzat A, Penet C, Martin C, Brice A, Campion D, Clerget-Darpoux F, Frebourg T (2000) APOE promoter polymorphisms do not confer independent risk for Alzheimer's disease in a French population. Eur J Hum Genet 8, 713-716.
44. Bullido MJ, Guallar-Castilĺon P, Artiga MJ, Ramos MC, Sastre I, Aldudo J, Frank A, Coria F, Rodríguez-Artalejo F,Valdivieso F (2000) Alzheimer's risk associated with human apolipoprotein E, alpha-2 macroglobulin and lipoprotein receptor related protein polymorphisms: absence of genetic interactions, and modulation by gender. Neurosci Lett 289, 213-216.
45. Scacchi R, Gambina G, Martini MC, Ruggeri M, Ferrari G, Silvestri M, Schiavon R, Corbo RM (2001) Polymorphisms of the apolipoprotein E gene regulatory region and of the LDL receptor gene in late-onset Alzheimer's disease in relation to the plasma lipidic pattern. Dement Geriatr Cogn Disord 12, 63-68.
46. Zill P, Engel R, Hampel H, Behrens S, Bürger K, Padberg F, Stübner S, Möller HJ, Ackenheil M, Bondy B (2001) Polymorphisms in the apolipoprotein E (APOE) gene in gerontopsychiatric patients. Eur Arch Psychiatry Clin Neurosci 251, 24-28.
47. Perry RT, Collins JS, Harrell LE, Acton RT, Go RC (2001) Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to age-matched controls. Am J Med Genet 105, 332-342.
48. Alvarez-Arcaya A, Combarros O, Llorca J, Śanchez-Guerra M, Berciano J, Ferńandez-Luna JL (2001) The -491 TT apolipoprotein E promoter polymorphism is associated with reduced risk for sporadic Alzheimer's disease. Neurosci Lett 304, 204-208.
49. Beyer K, Lao JI, Ǵomez M, Riutort N, Latorre P, Mate JL, Ariza A (2002) The Th1/E47cs-G apolipo- protein E (APOE) promoter allele is a risk factor for Alzheimer disease of very later onset. Neurosci Lett 326, 187-190.
50. Laws SM, Hone E, Taddei K, Harper C, Dean B, McClean C, Masters C, Lautenschlager N, Gandy SE, Martins RN (2002) Variation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E. Mol Psychiatry 7, 886-890.
51. Wakutani Y, Kowa H, Kusumi M, Yamagata K, Wada-Isoe K, Adachi Y, Takeshima T, Urakami K, Nakashima K (2002) Genetic analysis of vascular factors in Alzheimer's disease. Ann N Y Acad Sci 977, 232-238.
52. Roks G, Cruts M, Houwing-Duistermaat JJ, Dermaut B, Serneels S, Havekes LM, Hofman A, Breteler MM, Van Broeckhoven C, van Duijn CM (2002) Effect of the APOE- 491A/T promoter polymorphism on apolipoprotein E levels and risk of Alzheimer disease: The Rotterdam Study. Am J Med Genet 114, 570-573.
53. Tang GM, Zhang MY, Jiang SD, Qian YP,Wang DX (2003) A study on the relation between the apolipoprotein E promoter -427C/T polymorphism and Alzheimer's disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 20, 244-246.
54. Yang JD, Feng GY, Zhang J, Cheung J, St Clair D, He L, Ichimura K (2003) Apolipoprotein E -491 promoter polymorphism is an independent risk factor for Alzheimer's disease in the Chinese population. Neurosci Lett 350, 25-28.
55. Parra-Bonilla G, Arboleda G, Yunis J, Solano E, Pardo R, Arango G, Hedmont D, Arboleda H (2003) Haplogroup analysis of the risk associated with APOE promoter polymorphisms (-219T/G, -491A/T and -427T/C) in Colombian Alzheimer's disease patients. Neurosci Lett 349, 159-162.
56. Chalmers KA, Culpan D, Kehoe PG,Wilcock GK, Hughes A, Love S (2004) APOE promoter, ACEI and CYP46 polymorphisms and ?-amyloid in Alzheimer's disease. Neuroreport 15, 95-98.
57. Nicodemus KK, Stenger JE, Schmechel DE, Welsh-Bohmer KA, Saunders AM, Roses AD, Gilbert JR, Vance JM, Haines JL, Pericak-Vance MA, Martin ER (2004) Comprehensive association analysis of APOE regulatory region polymorphisms in Alzheimer disease. Neurogenetics 5, 201-208.
58. Juh́asz A, Palot́as A, Janka Z, Rimańoczy A, Palot́as M, B́odi N, Boda K, Zana M, Vincze G, Ḱalḿan J (2005) ApoE - 491A/T promoter polymorphism is not an independent risk factor, but associated with the epsilon4 allele in Hungarian Alzheimer's dementia population. Neurochem Res 30, 591-596.
59. Parker GR, Cathcart HM, Huang R, Lanham IS, Corder EH, Poduslo SE (2005) Apolipo- protein gene E4 allele promoter polymorphisms as risk factors for Alzheimer's disease. Psychiatr Genet 15, 271-275.
60. Grupe A, Abraham R, Li Y, Rowland C, Hollingworth P, Morgan A, Jehu L, Segurado R, Stone D, Schadt E, Karnoub M, Nowotny P, Tacey K, Catanese J, Sninsky J, Brayne C, Rubinsztein D, Gill M, Lawlor B, Lovestone S, Holmans P, O'Donovan M, Morris JC, Thal L, Goate A, Owen MJ, Williams J (2007). Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet 16, 865-873.
61. Lynch CA, Brazil J, Cullen B, Coakley D, Gill M, Lawlor BA, Hawi Z (2008) Apolipoprotein E promoter polymorphisms (- 491A/T and -427T/C) and Alzheimer's disease: no evidence of association in the Irish population. Ir J Med Sci 177, 29-33.
62. Bahia VS, Kok F, Marie SN, Shinjo SO, Caramelli P, Nitrini R (2008) Polymorphisms of APOE and LRP genes in Brazilian individuals with Alzheimer disease. Alzheimer Dis Assoc Disord 22, 61-65.
63. Trebunov́a M, Slab́a E, Habalov́a V, Gdovinov́a Z (2009) The role of the -427T/C apolipoprotein E promoter polymorphism in the pathogenesis of Alzheimer's disease, vascular dementia and mixed dementia. Neural Transm 116, 339-344.
64. Bizzarro A, Seripa D, Acciarri A, Matera MG, Pilotto A, Tiziano FD, Brahe C, Masullo C (2009) The complex interaction between APOE promoter and AD: an Italian case-control study. Eur J Hum Genet 17, 938-945.
65. Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, Walker LP, Younkin SG, Younkin CS, Younkin LH, Bisceglio GD, Ertekin-Taner N, Crook JE, Dickson DW, Petersen RC, Graff-Radford NR, Younkin SG (2009) Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet 41, 192-198.
66. Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J (2005) A method for meta-analysis of molecular association studies. Stat Med 24, 1291-1306.
67. Lau J, Antman Em, Jimenez-Silva J,Kupelnick B, Mosteller F, Chalmers TC (1992) Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 327, 248-254.
68. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39, 17-23.